Alzheimer’s devastates the lives of patients and their families, costing billions in care. New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access, even though these therapies are available in other countries. Reviewing how these medicines are valued is a first step towards bringing UK patients treatments that could give them the chance of better lives. | The Association of the British Pharm

11K views · 210 reactions | What industry wants from scientists The...